Skip To Main Content
Mengying Xia on Muck Rack

Mengying Xia

As seen in: PLOS ONE, MDPI, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mengying

Contact Mengying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer : The HARMONi-A Randomized Clinical Trial

|
By HARMONi-A Study Investigators, Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Longhua Sun, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Meiqi Shi, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Ying Liu, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Ruiqiang Ma, Hong Lu, Di Wu, Weineng Feng, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Mengying Xia, Dongmei Lu, Mingxiu Hu, Zhongmin Wang, Baiyong Li, Michelle Xia, Li Zhang, Junguo Lu
| JAMA: Journal of the American Medical Association Verified
Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small cell lung cancer after disease progression with EGFR tyrosine kinase inhibitor (TKI) therapy? Findings In this phase 3, randomized, double-blind trial, ivonescimab plus chemotherapy significantly improved overall survival (median, 16.8 vs 14.1 months) and the 30-month survival rate (29.1% vs 18.4%) compared with chemotherapy alone.
Open in Who Shared Issue with article?

Risk-enhancing factors and social determinants of health in risk assessment for atherosclerotic cardiovascular disease

|
By Yiyi Zhang, JaeJin An, Mengying Xia, Hui Zhou
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Zhang Y, An J, Xia M, Zhou H, Sun Y, Chung J, et al. (2024) Risk-enhancing factors and social determinants of health in risk assessment for atherosclerotic cardiovascular disease. PLoS ONE 19(10): e0312756.
Open in Who Shared Issue with article?

Cardiovascular Risk Associated With Social Determinants of Health at Individual and Area Levels

|
By Mengying Xia, JaeJin An, Monika M. Safford, Lisandro D. Colantonio
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question Does adding individual- or area-level social determinants of health (SDOH) to the pooled cohort equations (PCEs) or the Predicting Risk of CVD Events (PREVENT) equations improve accuracy of risk estimates for atherosclerotic cardiovascular disease (ASCVD)? Findings In this cohort study of 26 316 participants from 4 large US studies, both individual- and area-level of low education, low income, and unemployment were associated with an increased risk of incident ASCVD events.
Open in Who Shared Issue with article?
See all 5 articles